StemSation(TM) Reports Revenue Increase of 24% for the Quarter Ending June 30th, 2020

BOCA RATON, FL / ACCESSWIRE / August 19, 2020 / StemSation International, Inc. (OTC PINK:STSN) – a pioneer in the emerging category of dietary supplements called Stem Cell Nutrition, reported revenues for the second quarter ending June 30th , 2020 of $65,405 compared to revenues of $52,675 for the first quarter ending March 31st, 2020, representing an increase of 24% increase.

As start-up expenses subside, overhead costs also decreased by 18% in the second quarter. Ray Carter, StemSation President & CEO commented, “We are pleased to see the positive trends in our financials despite the COVID-19 challenges. We continue to see further growth as we move through Q3 and accelerate our marketing efforts”.

StemSation creates and markets all-natural consumer health products that support the two most recently discovered biological systems of the human body – stem cells and endocannabinoids, releasing its first three novel products to support immune health and joint & muscle health.

StemSation continues to expand its product reach globally, currently executing plans to enter the Latin American markets before the end of 2020.

StemSation is a company with a long-term ‘health mission’, ambitious research goals, and innovative, holistic approaches to health & wellness, and healthy longevity. Our product line shows a new pathway to wellness.

ABOUT STEMSATION INTERNATIONAL, INC.
StemSation International, Inc. (OTC PINK:STSN) develops, manufactures and distributes natural wellness products that support the stem cell and endocannabinoid systems in the human body through using a direct selling model in which Independent Wellness Advocates (“IWAs”) advertise and sell its products directly to consumers. StemSation is headquartered in Boca Raton, Florida and its website can be located at www.stemsation.global.

SAFE HARBOR STATEMENT
This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company’s control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

FOR INFORMATION, PLEASE CONTACT:
Nicholas B. Panza, Vice President
StemSation International, Inc.
7777 Glades Road
Suite 203
Boca Raton, FL 33434
npanza@stemsationusa.com
(561) 245-7454

SOURCE: StemSation International, Inc.

View source version on accesswire.com:
https://www.accesswire.com/602316/StemSationTM-Reports-Revenue-Increase-of-24-for-the-Quarter-Ending-June-30th-2020

Staff

Recent Posts

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

4 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

7 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

7 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

7 hours ago

Best Peptides for Anti-Aging: NAD+ Delivery Methods Compared as Telehealth Platforms Expand Access (2026 Analysis)

Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…

7 hours ago

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…

7 hours ago